NCT04620239

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

← Hub

Registry fields

Overall status: COMPLETED
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Study type: INTERVENTIONAL
Phase: PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: padeliporfin VTP
Lead sponsor: Steba Biotech S.A. (OTHER)

Cached at: 2026-07-21 21:31:12

View on ClinicalTrials.gov

Brief summary

This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase with the specific duration depending on the patient's response to treatment

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report